The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | C | Cardiovascular system | |
2 | C09 | Agents acting on the renin-angiotensin system | |
3 | C09C | Angiotensin II antagonists, plain |
Code | Title | |
---|---|---|
C09CA | Angiotensin II antagonists, plain |
Active Ingredient | Description | |
---|---|---|
Azilsartan medoxomil |
Azilsartan medoxomil is an orally active prodrug that is rapidly converted to the active moiety, azilsartan, which selectively antagonises the effects of angiotensin II by blocking its binding to the AT1 receptor in multiple tissues. Angiotensin II is the principal pressor agent of the RAAS, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. |
|
Candesartan |
Candesartan is an AIIRA, selective for AT1 receptors, with tight binding to and slow dissociation from the receptor. It has no agonist activity. The antagonism of the angiotensin II (AT1) receptors results in dose related increases in plasma renin levels, angiotensin I and angiotensin II levels, and a decrease in plasma aldosterone concentration. |
|
Eprosartan |
Eprosartan is a potent, synthetic, orally active non-biphenyl non-tetrazole angiotensin II receptor antagonist, which binds selectively to the AT1 receptor. |
|
Fimasartan |
Fimasartan, an angiotensin II receptor antagonist with selectivity for the AT1 receptor subtype, is a pyrimidinone-related heterocyclic compound. |
|
Irbesartan |
Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin-II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT1) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone concentration. |
|
Losartan |
Losartan is a synthetic oral angiotensin-II receptor (type AT1) antagonist. Antihypertensive activity and suppression of plasma aldosterone concentration are maintained, indicating effective angiotensin II receptor blockade. |
|
Olmesartan medoxomil |
Olmesartan medoxomil is a potent, orally active, selective angiotensin II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT1) receptors results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations. |
|
Tasosartan |
|
|
Telmisartan |
Telmisartan is an orally active and specific angiotensin II receptor (type AT1) antagonist. Telmisartan selectively binds the AT1 receptor. The binding is long-lasting. |
|
Valsartan |
Valsartan is an orally active, potent, and specific angiotensin II (Ang II) receptor antagonist. It acts selectively on the AT1-receptor subtype, which is responsible for the known actions of angiotensin II. |
Title | Information Source | Document Type | |
---|---|---|---|
AMIAS Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
APROVEL Tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
ATACAND Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
AVAPRO Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
BENICAR Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
BLOPRESS Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
CODAVAL Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
COZAAR Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
COZAAR Film-coated tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
COZAAR Powder and solvent for oral suspension | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
DIOVAN Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
EDARBI Tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
IFIRMASTA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
IRPRESTAN Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
LOSAR Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
MICARDIS Tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
MIZART Tablet | Pharmaceutical Benefits Scheme (AU) | MPI, EU: SmPC | |
OLMETEC Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
OMESAR Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
TELTARTAN Tablet | Pharmaceutical Benefits Scheme (AU) | MPI, EU: SmPC | |
TOLURA Tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
TROVAL Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
VAPRESS Film-coated tablet | Web Search | MPI, EU: SmPC | |
ZAARIO Film-coated tablet | Health Products Regulatory Authority (ZA) | MPI, Generic |